Prot #R1033-SRC-1239: A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of the Safety and Efficacy of 3-Month Subcutaneous REGN 1033 Treatment in Patients with Sarcopenia

Project: Research project

Project Details

StatusFinished
Effective start/end date5/5/145/5/17

Funding

  • Parexel (Prot #R1033-SRC-1239)
  • Regeneron Pharmaceuticals, Inc. (Prot #R1033-SRC-1239)